| 2026-06-02 |
Herantis Pharma Plc. |
Herantis reports positive FDA feedback and finalizes Phase 2a study design for HER-096 herantis.com ↗ |
| 2026-05-19 |
Herantis Pharma Plc. |
Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease herantis.com ↗ |
| 2026-03-16 |
Herantis Pharma Plc. |
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases herantis.com ↗ |
| 2026-02-19 |
Herantis Pharma Plc. |
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096 herantis.com ↗ |
| 2026-01-07 |
Herantis Pharma Plc. |
Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease herantis.com ↗ |
| 2025-11-26 |
Herantis Pharma Plc. |
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096 herantis.com ↗ |
| 2025-10-07 |
Herantis Pharma Plc. |
Inside information: Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease herantis.com ↗ |
| 2025-08-14 |
Herantis Pharma Plc. |
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease herantis.com ↗ |
| 2025-05-13 |
Herantis Pharma Plc. |
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease herantis.com ↗ |
| 2024-10-16 |
Herantis Pharma Plc. |
Herantis Pharma: HER-096 dosing started in the Phase 1b trial herantis.com ↗ |
| 2024-09-19 |
Herantis Pharma Plc. |
Herantis Pharma: Structural rationale of HER-096 design published in Nature Communications herantis.com ↗ |
| 2024-09-03 |
Herantis Pharma Plc. |
Herantis Pharma announces approval of clinical trial application for a Phase 1b trial with HER-096 in Parkinson’s disease herantis.com ↗ |
| 2024-05-20 |
Herantis Pharma Plc. |
Herantis Pharma has submitted a Clinical Trial Application (CTA) for a Phase 1b clinical trial of HER-096 herantis.com ↗ |
| 2024-03-04 |
Herantis Pharma Plc. |
Herantis Pharma: HER-096 promotes functional recovery and regeneration of stressed neurons – two poster presentations at AD/PD 2024 conference. herantis.com ↗ |
| 2023-12-01 |
Herantis Pharma Plc. |
Herantis Pharma announces publication of preclinical HER-096 data in Cell Chemical Biology journal herantis.com ↗ |
| 2023-10-25 |
Herantis Pharma Plc. |
Inside information: Herantis Pharma announces positive topline data from the Phase 1a clinical trial of HER-096, a disease modifying therapeutic developed for Parkinson’s disease herantis.com ↗ |
| 2023-08-22 |
Herantis Pharma Plc. |
Herantis Pharma Plc: First healthy volunteers dosed in the part 2 of the HER-096 Phase 1a clinical study herantis.com ↗ |
| 2023-07-04 |
Herantis Pharma Plc. |
Herantis Pharma Plc announcing start of recruitment of healthy volunteers for part 2 of the ongoing Phase 1a clinical study of HER-096 herantis.com ↗ |
| 2023-04-19 |
Herantis Pharma Plc. |
Herantis Pharma announces first healthy volunteer dosed in the Phase 1a clinical study for the Parkinson’s disease drug candidate, HER-096 herantis.com ↗ |
| 2023-02-20 |
Herantis Pharma Plc. |
Herantis Pharma announces approval of Clinical Trial Application (CTA) for a Phase 1 study for HER-096 herantis.com ↗ |
| 2022-12-19 |
Herantis Pharma Plc. |
Herantis Pharma announces submission of a Clinical Trial Application (CTA) for a Phase 1 study for HER-096 herantis.com ↗ |
| 2022-04-28 |
Herantis Pharma Plc. |
Herantis Pharma Announces Successful HER-096 Initial Results with Blood-Brain Barrier Penetration in Dogs herantis.com ↗ |
| 2022-03-24 |
Herantis Pharma Plc. |
Herantis Pharma Announces Successful HER-096 Initial Results with Nanoform Technology herantis.com ↗ |
| 2022-01-20 |
Herantis Pharma Plc. |
CEO transition; Herantis to focus on HER-096 herantis.com ↗ |
|